Jiangxi Synergy Pharmaceutical Co Ltd Net Asset Quality Index
Jiangxi Synergy Pharmaceutical Co Ltd net asset quality index. Jiangxi Synergy Pharmaceutical Co Ltd (300636) has a Net Asset Quality Index of 72.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.31 Billion minus total liabilities of CN¥927.61 Million yields net assets of CN¥2.38 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Jiangxi Synergy Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
Net asset quality index of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025. This chart shows how Jiangxi Synergy Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 72.0%, representing net assets of CN¥2.38 Billion against total assets of CN¥3.31 Billion CNY. Check Jiangxi Synergy Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Jiangxi Synergy Pharmaceutical Co Ltd Net Asset Quality Index by Year (2012–2025)
Jiangxi Synergy Pharmaceutical Co Ltd net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Jiangxi Synergy Pharmaceutical Co Ltd (300636) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 71.2% | CN¥2.37 Billion | CN¥3.32 Billion | CN¥955.80 Million | ▲ +1.7 pp |
| 2024 | 69.5% | CN¥2.31 Billion | CN¥3.32 Billion | CN¥1.01 Billion | ▲ +0.4 pp |
| 2023 | 69.1% | CN¥2.23 Billion | CN¥3.22 Billion | CN¥994.99 Million | ▲ +10.7 pp |
| 2022 | 58.4% | CN¥1.32 Billion | CN¥2.26 Billion | CN¥939.19 Million | ▲ +11.8 pp |
| 2021 | 46.6% | CN¥888.11 Million | CN¥1.91 Billion | CN¥1.02 Billion | ▼ -9.1 pp |
| 2020 | 55.6% | CN¥816.50 Million | CN¥1.47 Billion | CN¥651.17 Million | ▼ -13.9 pp |
| 2019 | 69.5% | CN¥706.31 Million | CN¥1.02 Billion | CN¥309.40 Million | ▼ -12.4 pp |
| 2018 | 81.9% | CN¥658.16 Million | CN¥803.62 Million | CN¥145.46 Million | ▼ -6.3 pp |
| 2017 | 88.2% | CN¥637.10 Million | CN¥722.28 Million | CN¥85.18 Million | ▲ +15.5 pp |
| 2016 | 72.7% | CN¥304.66 Million | CN¥418.96 Million | CN¥114.31 Million | ▲ +2.0 pp |
| 2015 | 70.7% | CN¥246.66 Million | CN¥348.64 Million | CN¥101.99 Million | ▲ +24.9 pp |
| 2014 | 45.9% | CN¥118.02 Million | CN¥257.30 Million | CN¥139.28 Million | ▲ +12.4 pp |
| 2013 | 33.5% | CN¥78.82 Million | CN¥235.43 Million | CN¥156.62 Million | ▲ +9.4 pp |
| 2012 | 24.1% | CN¥45.51 Million | CN¥188.82 Million | CN¥143.31 Million | — |